SLDB
Solid Biosciences Inc. NASDAQ Listed Jan 26, 2018$7.07
Mkt Cap $550.8M
52w Low $2.41
72.2% of range
52w High $8.87
50d MA $7.40
200d MA $6.16
P/E (TTM)
-3.6x
EV/EBITDA
-2.6x
P/B
3.5x
Debt/Equity
0.1x
ROE
-58.9%
P/FCF
-3.1x
RSI (14)
—
ATR (14)
—
Beta
2.58
50d MA
$7.40
200d MA
$6.16
Avg Volume
1.3M
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
141 Portland Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.51 | -0.50 | +2.0% | 7.12 | +4.8% | -1.3% | +0.3% | -6.2% | +1.5% | +8.6% | — |
| Nov 3, 2025 | AMC | -0.42 | -0.48 | -14.3% | 5.20 | -9.4% | -15.2% | -24.4% | -18.8% | -21.9% | -20.2% | — |
| Aug 12, 2025 | AMC | -0.51 | -0.42 | +17.6% | 6.04 | +0.0% | +10.6% | +2.2% | +1.2% | -0.2% | -4.0% | — |
| May 15, 2025 | AMC | -0.53 | -0.59 | -11.3% | 2.59 | +11.6% | +6.9% | +12.0% | +13.9% | +4.2% | +11.6% | — |
| Mar 6, 2025 | AMC | -0.79 | -0.89 | -12.7% | 5.50 | -4.5% | -1.5% | -7.5% | +2.0% | +4.2% | -6.4% | — |
| Nov 6, 2024 | AMC | -0.67 | -0.79 | -17.9% | 6.14 | -0.7% | -6.0% | -4.4% | -2.4% | -10.3% | -9.4% | — |
| Aug 13, 2024 | AMC | -0.68 | -0.61 | +10.3% | 7.29 | +3.6% | +14.5% | +22.5% | +21.7% | +27.3% | +28.0% | — |
| May 15, 2024 | AMC | -0.57 | -0.64 | -12.3% | 9.69 | -0.3% | -4.0% | -7.6% | -5.9% | -12.2% | -13.4% | — |
| Mar 13, 2024 | AMC | -1.01 | -1.00 | +1.0% | 12.23 | +11.9% | +0.4% | +7.0% | +9.2% | +20.6% | +8.5% | — |
| Nov 8, 2023 | AMC | -1.20 | -1.05 | +12.5% | 2.79 | -1.4% | -23.7% | -20.8% | -22.6% | -23.7% | -2.3% | — |
| Aug 14, 2023 | AMC | -1.52 | -1.25 | +17.8% | 3.85 | -1.6% | -2.3% | -2.3% | -3.6% | -2.3% | -2.1% | — |
| May 11, 2023 | AMC | -1.83 | -1.54 | +15.8% | 6.44 | +0.9% | -1.9% | -3.0% | -2.8% | -4.5% | -6.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | JP Morgan | Maintains | Overweight → Overweight | — | $6.68 | $6.85 | +2.5% | +8.2% | +15.7% | +6.4% | -2.8% | +7.8% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.03 | $7.14 | +1.6% | +1.6% | -5.0% | +2.8% | +10.0% | +1.1% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $7.12 | $7.46 | +4.8% | -1.3% | +0.3% | -6.2% | +1.5% | +8.6% |
| Mar 20 | Needham | Maintains | Buy → Buy | — | $7.12 | $7.46 | +4.8% | -1.3% | +0.3% | -6.2% | +1.5% | +8.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $7.72 | $7.45 | -3.5% | -0.1% | -5.3% | -3.1% | +0.5% | -7.8% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.72 | $7.45 | -3.5% | -0.1% | -5.3% | -3.1% | +0.5% | -7.8% |
| Mar 11 | Wedbush | Maintains | Outperform → Outperform | — | $8.18 | $8.00 | -2.2% | -5.6% | -5.7% | -10.6% | -8.6% | -5.1% |
| Feb 9 | Needham | Maintains | Buy → Buy | — | $6.52 | $6.57 | +0.8% | +5.2% | +6.3% | -1.8% | -6.7% | -5.1% |
| Jan 14 | Needham | Maintains | Buy → Buy | — | $5.16 | $5.16 | +0.0% | +12.6% | +9.7% | +6.0% | +8.9% | +19.4% |
| Nov 5 | Citigroup | Maintains | Buy → Buy | — | $4.41 | $4.51 | +2.3% | -10.9% | -4.3% | -7.9% | -5.9% | +2.7% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $4.41 | $4.51 | +2.3% | -10.9% | -4.3% | -7.9% | -5.9% | +2.7% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $5.20 | $4.71 | -9.4% | -15.2% | -24.4% | -18.8% | -21.9% | -20.2% |
| Nov 4 | Chardan Capital | Maintains | Buy → Buy | — | $5.20 | $4.71 | -9.4% | -15.2% | -24.4% | -18.8% | -21.9% | -20.2% |
| Aug 14 | JP Morgan | Maintains | Overweight → Overweight | — | $6.68 | $6.70 | +0.3% | -7.6% | -8.5% | -9.7% | -13.2% | -15.3% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $6.68 | $6.70 | +0.3% | -7.6% | -8.5% | -9.7% | -13.2% | -15.3% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $6.04 | $6.04 | +0.0% | +10.6% | +2.2% | +1.2% | -0.2% | -4.0% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.02 | $5.00 | -0.4% | -8.2% | -7.4% | -4.6% | -10.2% | -3.2% |
| Jun 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.25 | $4.31 | +1.4% | +6.8% | +8.7% | +13.6% | +8.5% | +7.8% |
| May 19 | Chardan Capital | Maintains | Buy → Buy | — | $2.77 | $2.69 | -2.9% | +4.7% | +6.5% | -2.5% | +4.3% | +1.4% |
| May 16 | Barclays | Maintains | Overweight → Overweight | — | $2.59 | $2.89 | +11.6% | +6.9% | +12.0% | +13.9% | +4.2% | +11.6% |
| May 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.59 | $2.89 | +11.6% | +6.9% | +12.0% | +13.9% | +4.2% | +11.6% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $2.59 | $2.89 | +11.6% | +6.9% | +12.0% | +13.9% | +4.2% | +11.6% |
| Mar 13 | JP Morgan | Maintains | Overweight → Overweight | — | $5.73 | $5.56 | -3.0% | -10.1% | -11.2% | -6.5% | -14.0% | -15.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.42 | $5.52 | +1.8% | -6.1% | +3.5% | +5.7% | -5.0% | -6.1% |
| Mar 7 | Chardan Capital | Maintains | Buy → Buy | — | $5.50 | $5.25 | -4.5% | -1.5% | -7.5% | +2.0% | +4.2% | -6.4% |
| Mar 7 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.50 | $5.25 | -4.5% | -1.5% | -7.5% | +2.0% | +4.2% | -6.4% |
| Feb 19 | Chardan Capital | Maintains | Buy → Buy | — | $5.30 | $5.45 | +2.8% | +22.1% | +13.2% | +9.1% | +5.3% | -0.2% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.68 | $3.52 | -4.3% | -10.1% | -16.0% | -14.7% | -11.7% | -11.1% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.03 | $3.75 | -6.9% | -8.7% | -17.9% | -23.3% | -22.1% | -19.4% |
| Dec 12 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $5.01 | $5.04 | +0.6% | -6.6% | -2.0% | -8.2% | -11.0% | -19.6% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.01 | $5.04 | +0.6% | -6.6% | -2.0% | -8.2% | -11.0% | -19.6% |
| Nov 12 | JP Morgan | Maintains | Overweight → Overweight | — | $5.99 | $5.86 | -2.2% | -8.0% | -7.2% | -11.4% | -19.0% | -16.5% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $5.87 | $6.00 | +2.2% | +2.0% | -6.1% | -5.3% | -9.5% | -17.4% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.14 | $6.10 | -0.7% | -6.0% | -4.4% | -2.4% | -10.3% | -9.4% |
| Aug 14 | Barclays | Maintains | Overweight → Overweight | — | $7.29 | $7.55 | +3.6% | +14.5% | +22.5% | +21.7% | +27.3% | +28.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.29 | $7.55 | +3.6% | +14.5% | +22.5% | +21.7% | +27.3% | +28.0% |
| Jul 15 | JP Morgan | Upgrade | Neutral → Overweight | — | $7.91 | $8.75 | +10.6% | +8.2% | +21.9% | +12.6% | -1.4% | +3.9% |
| Jun 24 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $6.46 | $6.67 | +3.3% | +2.5% | -10.2% | -11.8% | -11.1% | -12.2% |
| Jun 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.30 | $7.15 | +13.5% | +2.5% | +5.1% | -7.9% | -9.5% | -8.9% |
| May 31 | JP Morgan | Maintains | Neutral → Neutral | — | $7.64 | $7.83 | +2.5% | +8.1% | +8.0% | +2.7% | +1.7% | +1.0% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.95 | $8.99 | +0.4% | +1.9% | -4.9% | -6.3% | -12.7% | -13.0% |
| May 16 | Barclays | Maintains | Overweight → Overweight | — | $9.69 | $9.66 | -0.3% | -4.0% | -7.6% | -5.9% | -12.2% | -13.4% |
| Mar 18 | Barclays | Maintains | Overweight → Overweight | — | $13.08 | $13.33 | +1.9% | +2.1% | +12.8% | +1.5% | -3.5% | +5.1% |
| Mar 14 | Piper Sandler | Upgrade | Neutral → Overweight | — | $12.23 | $13.68 | +11.9% | +0.4% | +7.0% | +9.2% | +20.6% | +8.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.23 | $13.68 | +11.9% | +0.4% | +7.0% | +9.2% | +20.6% | +8.5% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.14 | $10.78 | -3.2% | +2.4% | +2.3% | +9.8% | +10.2% | +17.4% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $6.50 | $6.64 | +2.2% | +1.7% | +2.2% | +2.3% | +2.6% | +2.3% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $6.50 | $6.64 | +2.2% | +1.7% | +2.2% | +2.3% | +2.6% | +2.3% |
| Nov 10 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $6.36 | $6.31 | -0.8% | +2.2% | +3.9% | +4.4% | +4.6% | +4.9% |
| Oct 17 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $6.84 | $6.90 | +0.9% | +1.6% | +3.1% | -1.9% | -1.3% | -1.9% |
No insider trades available.
8-K · 5.02
!!! Very High
Barinthus Biotherapeutics plc -- 8-K 5.02: Executive Change
Barinthus Biotherapeutics appointed Douglas Swirsky as Chief Financial Officer, a leadership change potentially signaling strategic financial direction for the biotech company's operations.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I need more specific information about the executive change to provide meaningful analysis. Please share details about which executive changed roles, their responsibilities, and any replacement information from the 8-K filing.
Apr 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Solid Biosciences' ongoing gene therapy trial shows measurable biological markers of therapeutic effect in young DMD patients, validating the treatment approach and potentially supporting future regulatory approval for this rare disease indication.
Mar 12
8-K · 1.01
! Medium
Solid Biosciences Inc. -- 8-K 1.01: Equity Issuance
Solid Biosciences raised $240 million through an equity issuance, providing capital for research and development of its gene therapy programs.
Mar 6
Data updated apr 27, 2026 1:36am
· Source: massive.com